Literature DB >> 12496144

Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A.

Wyatt Byrd1, Steven R Mog, Frederick J Cassels.   

Abstract

The pathogenicity and immunogenicity induced in BALB/c mice by intranasal (i.n.) inoculation of enterotoxigenic Escherichia coli (ETEC) strains H10407 (O78:H11:CFA/I:LT(+):ST(+)) and B7A (O148:H28:CS6:LT(+):ST(+)) (two ETEC strains previously used in human challenge trials) were studied. The i.n. inoculation of BALB/c mice with large doses of ETEC strains H10407 and B7A caused illness and death. The H10407 strain was found to be consistently more virulent than the B7A strain. Following i.n. challenge with nonlethal doses of H10407 and B7A, the bacteria were cleared from the lungs of the mice at a steady rate over a 2-week period. Macrophages and neutrophils were observed in the alveoli and bronchioles, and lymphocytes were observed in the septa, around vessels, and in the pleura of the lungs in mice challenged with H10407 and B7A. In mice i.n. challenged with H10407, serum immunoglobulin G (IgG) and IgM antibodies were measured at high titers to the CFA/I and O78 lipopolysaccharide (LPS) antigens. In mice i.n. challenged with B7A, low serum IgG antibody titers were detected against CS6, and low serum IgG and IgM antibody titers were detected against O148 LPS. The serum IgG and IgM antibody titers against the heat-labile enterotoxin were equivalent in the H10407- and B7A-challenged mice. The CFA/I and O78 LPS antigens gave mixed T-helper cell 1-T-helper cell 2 (Th1-Th2) responses in which the Th2 response was greater than the Th1 response (i.e., stimulated primarily an antibody response). These studies indicate that the i.n. challenge of BALB/c mice with ETEC strains may provide a useful animal model to better understand the immunogenicity and pathogenicity of ETEC and its virulence determinants. This model may also be useful in providing selection criteria for vaccine candidates for use in primate and human trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496144      PMCID: PMC143142          DOI: 10.1128/IAI.71.1.13-21.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.

Authors:  M Isaka; Y Yasuda; S Kozuka; T Taniguchi; K Matano; J Maeyama; T Komiya; K Ohkuma; N Goto; K Tochikubo
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

2.  Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

Authors:  B Baras; M A Benoit; L Dupré; O Poulain-Godefroy; A M Schacht; A Capron; J Gillard; G Riveau
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Strategies for mucosal vaccine development.

Authors:  P N Boyaka; M Marinaro; J L Vancott; I Takahashi; K Fujihashi; M Yamamoto; F W van Ginkel; R J Jackson; H Kiyono; J R McGhee
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

4.  Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli.

Authors:  A M Alves; M O Lásaro; D F Almeida; L C Ferreira
Journal:  Immunol Lett       Date:  1998-07       Impact factor: 3.685

5.  Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans.

Authors:  D G Evans; R P Silver; D J Evans; D G Chase; S L Gorbach
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

6.  Pathogenesis of Escherichia coli diarrhea.

Authors:  H L DuPont; S B Formal; R B Hornick; M J Snyder; J P Libonati; D G Sheahan; E H LaBrec; J P Kalas
Journal:  N Engl J Med       Date:  1971-07-01       Impact factor: 91.245

7.  Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli.

Authors:  D J Freedman; C O Tacket; A Delehanty; D R Maneval; J Nataro; J H Crabb
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

8.  Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Authors:  K R Turbyfill; A B Hartman; E V Oaks
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

9.  Suckling mouse model for detection of heat-stable Escherichia coli enterotoxin: characteristics of the model.

Authors:  R A Giannella
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

10.  Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Authors:  G Douce; V Giannelli; M Pizza; D Lewis; P Everest; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

View more
  14 in total

1.  Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development.

Authors:  Julianne E Rollenhagen; Franca Jones; Eric Hall; Ryan Maves; Gladys Nunez; Nereyda Espinoza; Aisling O'Dowd; Michael G Prouty; Stephen J Savarino
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Capture efficiency of Escherichia coli in fimbriae-mediated immunoimmobilization.

Authors:  Zhiyong Suo; Xinghong Yang; Muhammedin Deliorman; Ling Cao; Recep Avci
Journal:  Langmuir       Date:  2011-12-28       Impact factor: 3.882

3.  Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.

Authors:  Jonathan Messika; Fatma Magdoud; Olivier Clermont; Dimitri Margetis; Stéphane Gaudry; Damien Roux; Catherine Branger; Didier Dreyfuss; Erick Denamur; Jean-Damien Ricard
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

4.  Establishment and Validation of Pathogenic CS17+ and CS19+ Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.

Authors:  Eric R Hall; Aisling O'Dowd; Julianne E Rollenhagen; Nereyda Espinoza; Gladys Nunez; Stephen J Savarino
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

5.  Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge.

Authors:  Wilson B Luiz; Juliana F Rodrigues; Joseph H Crabb; Stephen J Savarino; Luis C S Ferreira
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

6.  Identification and molecular characterization of EatA, an autotransporter protein of enterotoxigenic Escherichia coli.

Authors:  Seema K Patel; Jimmie Dotson; Kenneth P Allen; James M Fleckenstein
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections.

Authors:  Kurt Z Long; Jorge L Rosado; José Ignacio Santos; Meredith Haas; Abdullah Al Mamun; Herbert L DuPont; Nanda N Nanthakumar; Teresa Estrada-Garcia
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

8.  Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains.

Authors:  Kenneth P Allen; Mildred M Randolph; James M Fleckenstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

9.  Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli.

Authors:  Masoome Alerasol; Seyed Latif Mousavi Gargari; Shahram Nazarian; Samane Bagheri
Journal:  Iran Biomed J       Date:  2014

10.  Heat-Labile Toxin from Enterotoxigenic Escherichia coli Causes Systemic Impairment in Zebrafish Model.

Authors:  Camila Henrique; Maria Alice Pimentel Falcão; Luciana De Araújo Pimenta; Adolfo Luís Almeida Maleski; Carla Lima; Thais Mitsunari; Sandra Coccuzzo Sampaio; Mônica Lopes-Ferreira; Roxane Maria Fontes Piazza
Journal:  Toxins (Basel)       Date:  2021-06-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.